Company Applies to Mass-Produce Legal Amphetamines
Published Date: 7/16/2026
Notice
Summary
AMPAC Fine Chemicals LLC wants to become a big-time maker of certain controlled drugs like amphetamine and methylphenidate. This means they’ll handle large amounts of these substances, which are mostly used in medicines. People and companies can share their thoughts or ask for a hearing by September 14, 2026, so don’t miss the deadline!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-14286 — Importer of Controlled Substances Application: Catalent Greenville, Inc.
Catalent Greenville, Inc. wants to become an official importer of some powerful controlled substances, including LSD and related drugs. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 17, 2026. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
2026-14137 — Shane Lydon, M.D.; Decision and Order
Dr. Shane Lydon's license to handle controlled substances in Maine has been revoked because he lost his state authority and didn’t ask for a hearing. This means he can no longer prescribe or manage these drugs, effective immediately. Anyone relying on his registration should update their records and note this change to avoid legal trouble.
2026-14135 — David Enright, M.D.; Decision and Order
Dr. David Enright from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-14136 — Barlow St-Clair Lynch, M.D.; Decision and Order
Dr. Barlow St-Clair Lynch from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Previous / Next Documents
Previous: 2026-14283 — Process for FDA Data Requests To Inform Certain Over-the-Counter Monograph Drug Activities; Procedure
The FDA is rolling out a clear process to ask the public for data to help update rules about over-the-counter (OTC) drugs. This means anyone interested in OTC drug safety and use can share info that might change how these medicines are regulated. The new process starts now and aims to make drug updates smarter and faster, with no direct costs to the public but big benefits for safer medicines.
Next: 2026-14285 — Importer of Controlled Substances Application: Unither Manufacturing LLC
Unither Manufacturing LLC wants to become an official importer of a controlled drug called methylphenidate, which is used to treat conditions like ADHD. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 17, 2026. This move could affect how this medicine gets into the U.S., but no direct costs or changes for the public are expected right now.